Longevity Patent Family

ANTI-C5 AGENT FOR TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION (AMD) OR GEOGRAPHIC ATROPHY SECONDARY TO DRY AMD

Source-linked patent metadata for ANTI-C5 AGENT FOR TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION (AMD) OR GEOGRAPHIC ATROPHY SECONDARY TO DRY AMD, including priority, record stage and longevity-topic connections.

Patent-family snapshot

Publication stage not classified

Family grouping brings related publications for the same invention together, instead of counting every national filing as a separate technology.

Representative publication
ES3079237T3
Earliest priority
October 27, 2019
Latest publication
September 23, 2026
Family publications
1
Patent offices
1
Patent-to-Evidence Translation Map

What is happening in the same scientific field?

These connections share a longevity topic with this patent record. They do not prove that the listed evidence, trials, funders, or universities validate, finance, own, or support this invention.

Organizations

Organizations named in this family

Astellas US LLCApplicant
Longevity context

Topics connected by metadata

Vision ageing88% metadata match
Knowledge connections

What this family cites

Earlier patent references
0
Scientific and other non-patent references
0
Priority dates represented
3

References show which earlier documents the patent record points to. They do not validate the invention or prove that cited research supports its claims.

Technical classification

How the patent office classifies this invention

No patent classification is available in the retained record.

Verify in the original patent source →